Drybench Patent.
Patent and exclusivity dates from July to December 2024 for NDAs, as FDA's Orange Book lists them
Each patent and exclusivity date from July to December 2024 that FDA's Orange Book lists for an NDA, as captured on 14 October 2026. That capture lists a patent or exclusivity for 1,411 NDAs. Each entry is named by its rule and linked to its NDA page. A date here belongs to one patent or one exclusivity on the products named; the same NDA may have other listed dates, earlier or later, so no date here stands for a product.
FDA capture · review pending. Each date is shown as captured from FDA's Orange Book files. Dates are as FDA lists them, and Drybench computes none; patent dates are submitted by the applicant, and FDA does not verify them. Spreadsheet day numbers are shown as dates; a cell that cannot be read as one date is left off this page and shown as written on its NDA page. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
This page covers every NDA whose Orange Book capture lists a patent or exclusivity. It does not cover ANDAs or any BLA. NCE exclusivity dates are here as FDA lists them; NCE-1 dates, computed from them, are on the NCE-1 calendar.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
NCE-1, one year before a listed NCE exclusivity date and the one date Drybench computes, is on its own page: NCE-1 dates from the Orange Book
Non-patent exclusivity (6)
16 Jul 2024 · NDA 212819 · CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
NCE exclusivity
exclusivity.txt line 1,121- Definition
- New chemical entity (to be checked against FDA's list)
- Product numbers
- 001
14 Aug 2024 · NDA 212862 · PRETOMANID
NCE exclusivity
exclusivity.txt line 1,125- Definition
- New chemical entity (to be checked against FDA's list)
- Product numbers
- 001
19 Aug 2024 · NDA 211672 · LEFAMULIN ACETATE
NCE exclusivity
exclusivity.txt line 980- Definition
- New chemical entity (to be checked against FDA's list)
- Product numbers
- 001
19 Aug 2024 · NDA 211673 · LEFAMULIN ACETATE
NCE exclusivity
exclusivity.txt line 982- Definition
- New chemical entity (to be checked against FDA's list)
- Product numbers
- 001
14 Nov 2024 · NDA 209445 · CEFIDEROCOL SULFATE TOSYLATE
NCE exclusivity
exclusivity.txt line 785- Definition
- New chemical entity (to be checked against FDA's list)
- Product numbers
- 001
7 Dec 2024 · NDA 215650 · CLINDAMYCIN PHOSPHATE
NP exclusivity
exclusivity.txt line 1,604- Definition
- New product (to be checked against FDA's list)
- Product numbers
- 001